

# James N Ingle

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7782919/publications.pdf>

Version: 2024-02-01

105  
papers

6,078  
citations

81743

39  
h-index

74018

75  
g-index

108  
all docs

108  
docs citations

108  
times ranked

6846  
citing authors

#	ARTICLE	IF	CITATIONS
1	Anastrozole Regulates Fatty Acid Synthase in Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 206-216.	1.9	4
2	Estrogen receptor beta repurposes EZH2 to suppress oncogenic NF $\kappa$ B/p65 signaling in triple negative breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 20.	2.3	9
3	Identification of Two Genetic Loci Associated with Leukopenia after Chemotherapy in Patients with Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3342-3355.	3.2	3
4	Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307). <i>Supportive Care in Cancer</i> , 2021, 29, 2509-2517.	1.0	17
5	A clinical calculator to predict disease outcomes in women with triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 557-566.	1.1	19
6	Development and Characterization of Novel Endoxifen-Resistant Breast Cancer Cell Lines Highlight Numerous Differences from Tamoxifen-Resistant Models. <i>Molecular Cancer Research</i> , 2021, 19, 1026-1039.	1.5	2
7	ZNF423 modulates the AMP-activated protein kinase pathway and metformin response in a single nucleotide polymorphisms, estrogen and selective estrogen receptor modulator dependent fashion. <i>Pharmacogenetics and Genomics</i> , 2021, 31, 155-164.	0.7	1
8	Patient-Derived Xenograft Engraftment and Breast Cancer Outcomes in a Prospective Neoadjuvant Study (BEAUTY). <i>Clinical Cancer Research</i> , 2021, 27, 4696-4699.	3.2	7
9	Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early-stage Breast Cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1038-1049.	2.3	5
10	Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1 positive Triple-negative Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5628-5637.	3.2	32
11	Single-nucleotide polymorphism biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancer. <i>Pharmacogenetics and Genomics</i> , 2021, 31, 1-9.	0.7	0
12	Predicting the clinical outcomes and benefit from letrozole after 5 years of treatment with aromatase inhibitors for early breast cancer: analysis from CCTG MA.17R. <i>Breast Cancer Research and Treatment</i> , 2021, , 1.	1.1	0
13	Optimized immunohistochemical detection of estrogen receptor beta using two validated monoclonal antibodies confirms its expression in normal and malignant breast tissues. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 241-249.	1.1	31
14	Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307. <i>Journal of the National Cancer Institute</i> , 2020, 112, 698-707.	3.0	48
15	Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 505.	3.4	51
16	Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 51.	2.2	11
17	Functional genomics based on germline genome-wide association studies of endocrine therapy for breast cancer. <i>Pharmacogenomics</i> , 2020, 21, 615-625.	0.6	1
18	Baseline estrogen levels in postmenopausal women participating in the MAP.3 breast cancer chemoprevention trial. <i>Menopause</i> , 2020, 27, 693-700.	0.8	15

#	ARTICLE	IF	CITATIONS
19	Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients. <i>Npj Breast Cancer</i> , 2020, 6, 4.	2.3	49
20	Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor $\beta$ . <i>Clinical Cancer Research</i> , 2020, 26, 2986-2996.	3.2	17
21	Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action. <i>JCI Insight</i> , 2020, 5, .	2.3	16
22	Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 709-716.	1.1	54
23	Tamoxifen Metabolism and Breast Cancer Recurrence: A Question Unanswered by CYPTAM. <i>Journal of Clinical Oncology</i> , 2019, 37, 1982-1983.	0.8	17
24	The lncRNA MIR2052HG regulates ER $\beta$ levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1. <i>Breast Cancer Research</i> , 2019, 21, 47.	2.2	36
25	4-Hydroxytamoxifen enhances sensitivity of estrogen receptor $\beta$ -positive breast cancer to docetaxel in an estrogen and ZNF423 SNP-dependent fashion. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 567-578.	1.1	6
26	Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome-Wide Association Study: Functional Epistatic Interaction Between <i>SLC38A7</i> and <i>ALPPL2</i> . <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 219-227.	2.3	10
27	TCL1A, a Novel Transcription Factor and a Coregulator of Nuclear Factor $\kappa$ B p65: Single Nucleotide Polymorphism and Estrogen Dependence. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 365, 700-710.	1.3	9
28	Ketamine and ketamine metabolites as novel estrogen receptor ligands: Induction of cytochrome P450 and AMPA glutamate receptor gene expression. <i>Biochemical Pharmacology</i> , 2018, 152, 279-292.	2.0	35
29	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2D6</i> and Tamoxifen Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 770-777.	2.3	244
30	Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 639-647.	1.1	21
31	Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor-Treated Patients: CCTG MA.27. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1003-1008.	3.0	19
32	Pharmacogenomic Discovery to Function and Mechanism: Breast Cancer as a Case Study. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 243-252.	2.3	7
33	Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 89-99.	1.1	74
34	ER $\beta$ -mediated induction of cystatins results in suppression of TGF $\beta$ signaling and inhibition of triple-negative breast cancer metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E9580-E9589.	3.3	47
35	SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathway. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 189-199.	1.1	17
36	Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	61

#	ARTICLE	IF	CITATIONS
37	Breast cancer chemoprevention pharmacogenomics: Deep sequencing and functional genomics of the ZNF423 and CTSO genes. <i>Npj Breast Cancer</i> , 2017, 3, 30.	2.3	18
38	Skeletal and Uterotrophic Effects of Endoxifen in Female Rats. <i>Endocrinology</i> , 2017, 158, 3354-3368.	1.4	6
39	TCL1A Single-Nucleotide Polymorphisms and Estrogen-Mediated Toll-Like Receptor-MYD88-Dependent Nuclear Factor- $\kappa$ B Activation: Single-Nucleotide Polymorphism and Selective Estrogen Receptor Modulator-Dependent Modification of Inflammation and Immune Response. <i>Molecular Pharmacology</i> , 2017, 92, 175-184.	1.0	18
40	Calmodulin-like protein 3 is an estrogen receptor alpha coregulator for gene expression and drug response in a SNP, estrogen, and SERM-dependent fashion. <i>Breast Cancer Research</i> , 2017, 19, 95.	2.2	22
41	Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study. <i>Breast Cancer Research</i> , 2017, 19, 130.	2.2	53
42	First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3391-3400.	0.8	58
43	SNPs near the cysteine proteinase cathepsin O gene (CTSO) determine tamoxifen sensitivity in ER $\pm$ -positive breast cancer through regulation of BRCA1. <i>PLoS Genetics</i> , 2017, 13, e1007031.	1.5	22
44	A comprehensive analysis of breast cancer microbiota and host gene expression. <i>PLoS ONE</i> , 2017, 12, e0188873.	1.1	111
45	ER $\beta$ inhibits cyclin dependent kinases 1 and 7 in triple negative breast cancer. <i>Oncotarget</i> , 2017, 8, 96506-96521.	0.8	35
46	Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy. <i>Cancer Research</i> , 2016, 76, 7012-7023.	0.4	47
47	Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. <i>New England Journal of Medicine</i> , 2016, 375, 209-219.	13.9	507
48	Estrogen, SNP-Dependent Chemokine Expression and Selective Estrogen Receptor Modulator Regulation. <i>Molecular Endocrinology</i> , 2016, 30, 382-398.	3.7	27
49	Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients. <i>Clinical Breast Cancer</i> , 2016, 16, 82-86.	1.1	37
50	Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole. <i>Steroids</i> , 2015, 99, 32-38.	0.8	38
51	Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance). <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	52
52	Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Germline Pharmacogenetic Studies. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	37
53	Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG-ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307.. <i>Journal of Clinical Oncology</i> , 2015, 33, 503-503.	0.8	16
54	The Effects of a Novel Hormonal Breast Cancer Therapy, Endoxifen, on the Mouse Skeleton. <i>PLoS ONE</i> , 2014, 9, e98219.	1.1	8

#	ARTICLE	IF	CITATIONS
55	ER <sup>±</sup> : characterization, prognosis, and evaluation of treatment strategies in ER <sup>±</sup> -positive and -negative breast cancer. BMC Cancer, 2014, 14, 749.	1.1	53
56	Phase III Comparison of Tamoxifen Versus Tamoxifen Plus Ovarian Function Suppression in Premenopausal Women With Node-Negative, Hormone Receptor-Positive Breast Cancer (E-3193). J Clin Oncol. 2014;32(10):1183-1191. doi:10.1200/JCO.2013.52.4000	0.8	118
57	Quality of Life in MAP.3 (Mammary Prevention 3): A Randomized, Placebo-Controlled Trial Evaluating Exemestane for Prevention of Breast Cancer. Journal of Clinical Oncology, 2014, 32, 1427-1436.	0.8	49
58	Re: Concordance Between CYP2D6 Genotypes Obtained From Tumor-Derived and Germline DNA. Journal of the National Cancer Institute, 2014, 106, .	3.0	4
59	Postmenopausal women with hormone receptor-positive breast cancer: Balancing benefit and toxicity from aromatase inhibitors. Breast, 2013, 22, S180-S183.	0.9	19
60	Pharmacogenomics of endocrine therapy in breast cancer. Journal of Human Genetics, 2013, 58, 306-312.	1.1	18
61	Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27 A Randomized Controlled Phase III Trial. Journal of Clinical Oncology, 2013, 31, 1398-1404.	0.8	218
62	TSPYL5 SNPs: Association with Plasma Estradiol Concentrations and Aromatase Expression. Molecular Endocrinology, 2013, 27, 657-670.	3.7	49
63	Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention. Cancer Discovery, 2013, 3, 812-825.	7.7	61
64	Endoxifen's Molecular Mechanisms of Action Are Concentration Dependent and Different than That of Other Anti-Estrogens. PLoS ONE, 2013, 8, e54613.	1.1	38
65	Exemestane for Breast-Cancer Prevention in Postmenopausal Women. New England Journal of Medicine, 2011, 364, 2381-2391.	13.9	847
66	Overview of adjuvant trials of aromatase inhibitors in early breast cancer. Steroids, 2011, 76, 765-767.	0.8	24
67	Variation in Anastrozole Metabolism and Pharmacodynamics in Women with Early Breast Cancer. Cancer Research, 2010, 70, 3278-3286.	0.4	63
68	Functional Genetic Polymorphisms in the Aromatase Gene CYP19 Vary the Response of Breast Cancer Patients to Neoadjuvant Therapy with Aromatase Inhibitors. Cancer Research, 2010, 70, 319-328.	0.4	102
69	HER2 and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial. Journal of Clinical Oncology, 2010, 28, 4307-4315.	0.8	216
70	The Tamoxifen Metabolite, Endoxifen, Is a Potent Antiestrogen that Targets Estrogen Receptor $\beta$ for Degradation in Breast Cancer Cells. Cancer Research, 2009, 69, 1722-1727.	0.4	200
71	Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen. JAMA - Journal of the American Medical Association, 2009, 302, 1429.	3.8	468
72	Pharmacogenomics of tamoxifen and aromatase inhibitors. Cancer, 2008, 112, 695-699.	2.0	41

#	ARTICLE	IF	CITATIONS
73	Estrogen receptor $\hat{1}\pm/\hat{1}^2$ isoforms, but not $\hat{1}^2cx$ , modulate unique patterns of gene expression and cell proliferation in Hs578T cells. <i>Journal of Cellular Biochemistry</i> , 2007, 101, 1125-1147.	1.2	49
74	Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. <i>Breast Cancer Research and Treatment</i> , 2006, 99, 295-300.	1.1	89
75	Fulvestrant in Women With Advanced Breast Cancer After Progression on Prior Aromatase Inhibitor Therapy: North Central Cancer Treatment Group Trial N0032. <i>Journal of Clinical Oncology</i> , 2006, 24, 1052-1056.	0.8	128
76	Adjuvant Endocrine Therapy for Postmenopausal Women with Early Breast Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 1031s-1036s.	3.2	17
77	Aromatase inhibitors for therapy of advanced breast cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2005, 95, 113-119.	1.2	29
78	Endocrine therapy trials of aromatase inhibitors for breast cancer in the adjuvant and prevention settings. <i>Clinical Cancer Research</i> , 2005, 11, 900s-5s.	3.2	22
79	Sequencing of Endocrine Therapy in Postmenopausal Women with Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 362s-367s.	3.2	18
80	Hormonal Therapy: Current and New Directions. <i>Breast Journal</i> , 2003, 9, S17-S21.	0.4	1
81	Aromatase inhibitors versus tamoxifen for management of postmenopausal breast cancer in the advanced disease and neoadjuvant settings. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2003, 86, 313-319.	1.2	14
82	Adjuvant endocrine therapy in postmenopausal breast cancer. <i>Clinical Cancer Research</i> , 2003, 9, 480S-5S.	3.2	4
83	Estrogen as therapy for breast cancer. <i>Breast Cancer Research</i> , 2002, 4, 133-6.	2.2	56
84	Sequencing of Hormonal Therapy in Breast Cancer. <i>Breast Journal</i> , 2002, 8, 332-337.	0.4	3
85	Multicultural aspects of breast cancer etiology workshop. , 2000, 88, 1265-1266.		0
86	Phase I Evaluation of Preirradiation Chemotherapy with Carmustine and Cisplatin and Accelerated Radiation Therapy in Patients with High-grade Gliomas. <i>Neurosurgery</i> , 1999, 44, 67-73.	0.6	19
87	Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis. <i>Breast Cancer Research and Treatment</i> , 1999, 54, 117-122.	1.1	130
88	Prognostic factors in elderly women with metastatic breast cancer treated with tamoxifen: An analysis of patients entered on four prospective clinical trials. <i>Cancer</i> , 1996, 77, 683-690.	2.0	32
89	Comparison of estrogen receptor determinations by a biochemical ligand-binding assay and immunohistochemical staining with monoclonal antibody ER1D5 in females with lymph node positive breast carcinoma entered on two prospective clinical trials. <i>Cancer</i> , 1996, 78, 764-772.	2.0	58
90	Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol. <i>Cancer</i> , 1994, 74, 2956-2963.	2.0	93

#	ARTICLE	IF	CITATIONS
91	Patterns of tumor relapse following mastectomy and adjuvant systemic therapy in patients with axillary lymph node-positive breast cancer. Impact of clinical, histopathologic, and flow cytometric factors. <i>Cancer</i> , 1993, 72, 1247-1260.	2.0	87
92	Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis. <i>Cancer</i> , 1991, 67, 886-891.	2.0	95
93	A double-blind trial of tamoxifen plus prednisolone versus tamoxifen plus placebo in postmenopausal women with metastatic breast cancer. A collaborative trial of the north central cancer treatment group and mayo clinic. <i>Cancer</i> , 1991, 68, 34-39.	2.0	38
94	Results of salvage hormonal therapy and salvage chemotherapy in women failing adjuvant chemotherapy after mastectomy for breast cancer. <i>Breast Cancer Research and Treatment</i> , 1989, 13, 135-142.	1.1	20
95	Randomized trial to evaluate the addition of tamoxifen to cyclophosphamide, 5-fluorouracil, prednisone adjuvant therapy in premenopausal women with node-positive breast cancer. <i>Cancer</i> , 1989, 63, 1257-1264.	2.0	27
96	Randomized clinical trial of CFP versus CMFP in women with metastatic breast cancer. <i>Cancer</i> , 1989, 63, 1931-1937.	2.0	10
97	Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 1987, 20, 219-222.	1.1	98
98	A phase II study of cis-diamminedichloroplatinum and 5-fluorouracil in advanced upper aerodigestive neoplasms. <i>Head &amp; Neck</i> , 1984, 6, 1020-1023.	0.3	26
99	Additive hormonal therapy in women with advanced breast cancer. <i>Cancer</i> , 1984, 53, 766-777.	2.0	36
100	Cyclophosphamide, Doxorubicin, and Cisplatin Combined in the Treatment of Advanced Sarcomas. <i>Medical and Pediatric Oncology</i> , 1983, 11, 319-321.	1.0	10
101	Cis-diamminedichloroplatinum (II) administered by 24-hour infusion in the treatment of patients with advanced upper aerodigestive cancer. <i>Cancer</i> , 1983, 51, 2020-2023.	2.0	18
102	Phase II study of high-dose tamoxifen (NSC-180973) in patients with disseminated malignant melanoma. <i>Cancer</i> , 1982, 49, 1353-1354.	2.0	26
103	Cyclophosphamide, adriamycin, and cis-diamminedichloroplatinum (II) in the treatment of patients with advanced head and neck cancer. <i>Cancer</i> , 1981, 47, 240-244.	2.0	39
104	Chemotherapy for advanced head and neck cancer with the combination adriamycin, cyclophosphamide, and cis-diamminedichloroplatinum (II): Preliminary assessment of a one-day vs. three-day drug regimen. <i>Cancer</i> , 1981, 47, 2549-2551.	2.0	22
105	Estrogen receptors in patients with malignant melanoma. <i>Cancer</i> , 1980, 46, 1785-1786.	2.0	54